| Original language | English (US) |
|---|---|
| Pages (from-to) | 786-787 |
| Number of pages | 2 |
| Journal | The Lancet Neurology |
| Volume | 20 |
| Issue number | 10 |
| DOIs | |
| State | Published - Oct 2021 |
ASJC Scopus subject areas
- Clinical Neurology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: The Lancet Neurology, Vol. 20, No. 10, 10.2021, p. 786-787.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Neuropathology of progressive supranuclear palsy after treatment with tilavonemab
AU - Koga, Shunsuke
AU - Dickson, Dennis W.
AU - Wszolek, Zbigniew K.
N1 - Funding Information: SK receives research support by a Jaye F and Betty F Dyer Foundation Fellowship in progressive supranuclear palsy research and CurePSP. DWD receives support from the NIH (U54 NS100693, UG3-NS104095, R01 AG062348), and Tau Consortium. ZKW is partially supported by the NIH/NIA and NIH/NINDS (1U19AG063911, Federal Award Identification Number U19AG063911), Mayo Clinic Center for Regenerative Medicine, Mayo Clinic in Florida Focused Research Team Program, the gifts from The Sol Goldman Charitable Trust, and the Donald G and Jodi P Heeringa Family, the Haworth Family Professorship in Neurodegenerative Diseases fund, and The Albertson Parkinson's Research Foundation. He serves as principal investigator or coprincipal investigator on Biogen (228PD201), Biohaven Pharmaceuticals (BHV4157-206 and BHV3241-301), Neuraly, (NLY01-PD-1), and Vigil Neuroscience, (VGL101-01.001) grants. He serves as coprincipal investigator of the Mayo Clinic APDA Center for Advanced Research and as an external advisory board member for the Vigil Neuroscience. He served as Mayo Clinic Florida site principal investigator for the protocols: AbbVie, M15–562 “A study to assess efficacy, safety, tolerability, and pharmacokinetics of ABBV-8E12 in subjects with progressive supranuclear palsy (PSP)”, AbbVie, M15–563 “An extension study of ABBV-8E12 in progressive supranuclear palsy (PSP)”, and C2N Diagnostics C2N-8E12-WW-104 “Safety, tolerability, and pharmacokinetics of C2N-8E12 in subjects with progressive supranuclear palsy”.
PY - 2021/10
Y1 - 2021/10
UR - http://www.scopus.com/inward/record.url?scp=85114827684&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85114827684&partnerID=8YFLogxK
U2 - 10.1016/S1474-4422(21)00283-0
DO - 10.1016/S1474-4422(21)00283-0
M3 - Letter
C2 - 34536399
AN - SCOPUS:85114827684
SN - 1474-4422
VL - 20
SP - 786
EP - 787
JO - The Lancet Neurology
JF - The Lancet Neurology
IS - 10
ER -